Publication Date
2021
Journal Title
BMJ Case Rep
Abstract
© 2021 BMJ Publishing Group. All rights reserved. Convalescent plasma, which contains antibodies from recovered individuals, has been used as an effective treatment for infectious diseases in the past and is currently being used as a potential treatment option for COVID-19. Multiple studies have reported this treatment to be safe. We report a case of a patient who developed acute respiratory distress syndrome (ARDS) with features suggestive of transfusion-related acute lung injury after being treated with convalescent plasma for COVID-19. We emphasise the need to be aware of the potential risk of transfusion reactions and disease worsening with convalescent plasma administration and to weigh the risk and benefits of this therapy before administration to patients and propose that further study be done regarding the potential risks of convalescent plasma.
Volume Number
14
Issue Number
1
Pages
e239762
Document Type
Article
Status
Northwell Researcher; Northwell Resident
Facility
Northwell Health
Additional Departments
COVID-19 Publications
PMID
DOI
10.1136/bcr-2020-239762